Cassava Sciences (SAVA)

• Market cap: $104M
• 1 day: -1.82%
• 5 days: -5.26%
• 1 month: -8.09%
• 3 months: 1.41%
• 6 months: -10.74%
• Year to date: -21.45%
• 1 year: -92.74%
• 5 years: -31.86%
• 10 years: -82.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $838K

8.3% less ownership

Funds ownership: 32.73% [Q1] → 24.44% (-8.3%) [Q2]

16% less capital invested

Capital invested by funds: $25.6M [Q1] → $21.4M (-$4.16M) [Q2]

18% less funds holding

Funds holding: 117 [Q1] → 96 (-21) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 32

51% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 37